All In Biotech

Drug Trial Radar · NCT00047632

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma.

Last checked: Nov 20, 2026Latest source record: Nov 1, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 847 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

847

Actual

Start

Oct 2001

Primary completion

Not stated

Study completion Feb 2006

Sponsor

Lead sponsor
InterMuneIndustry
Sponsor type
Industry
First posted
Oct 11, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary peritoneal carcinoma compared with chemotherapy alone; 2) how effective interferon gamma-1b plus standard chemotherapy is in preventing the progression or return of cancer; 3) the effects on quality of life; and 4) the safety of interferon gamma-1b combined with standard chemotherapy compared to chemotherapy alone.

Conditions

  • Ovarian Carcinoma
  • Peritoneal Carcinoma

Interventions

  • Interferon gamma-1bDrug

    100 mcg, SQ, 3x per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival time assessed at end of studyTime frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • InterMune, Inc.

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.